# US 6,727,281 B2 · Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,281 B2
- Document ID: US6727281B2
- Status: Granted
- Kind: B2
- Application number: 10/201,336
- Filed: 2002-07-23
- Published: 2002-12-05
- Granted: 2004-04-27
- Earliest claimed: 1997-08-28
- Assignees: Novartis AG
- Inventors: Roger A. Fujimoto; Leslie W. McQuire; Benjamin B. Mugrage; John H. van Duzer
- Web page: https://patentgrep.com/patent/US6727281B2

## CPC

- C07C 229/42: with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.

## Claims

### Claim 1

A compound of formula I
wherein R is methyl or ethyl;
R1 is chloro or fluoro;
R2 is hydrogen or fluoro;
R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;
R4 is hydrogen or fluoro; and
R5 is methyl;
or a pharmaceutically acceptable salt thereof;
or a pharmaceutically acceptable prodrug ester thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen; R3 is hydrogen, fluoro, chloro, methyl or hydroxy; R4 is hydrogen; and R5 is methyl; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable prodrug ester thereof.

### Claim 3 (depends on 1)

A compound according to claim 1 which is 5-ethyl-2-(2′,4′-dichloro-6′-methylanilino)phenylacetic acid wherein in formula I R is ethyl; R1 is chloro; R2 is hydrogen; R3 is chloro; R4 is hydrogen; and R5 is methyl; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising an effective cyclooxygenase-2 inhibiting amount of a compound of claim 1 which is substantially free of cyclooxygenase-1 inhibiting activity in combination with one or more pharmaceutically acceptable carriers.

### Claim 5 (depends on 3)

A pharmaceutical composition comprising an effective cyclooxygenase-2 inhibiting amount of a compound of claim 3 which is substantially free of cyclooxygenase-1 inhibiting activity in combination with one or more pharmaceutically acceptable carriers.

### Claim 6 (depends on 1)

A method of treating cyclooxygenase-2 dependent disorders in mammals while substantially eliminating undesirable side effects associated with cyclooxygenase-1 inhibiting activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of claim 1 which is substantially free of cyclooxygenase-1 inhibiting activity.

### Claim 7 (depends on 1)

A method of selectively inhibiting cyclooxygenase-2 activity in a mammal without substantially inhibiting cycloxygenase-1 activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of claim 1 which is substantially free of cyclooxygenase-1 inhibiting activity.

### Claim 8 (depends on 1)

A method of treating rheumatoid arthritis, osteoarthritis, pain, inflammation in mammals which comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of claim 1 which is substantially free of gastrointestinal ulceration.

### Claim 9 (depends on 1)

A method of treating ocular inflammatory disorders, glaucoma or dry eye disease in mammals which comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of claim 1.

### Claim 10 (depends on 1)

A method for the preparation of a compound of formula I according to claim 1 which comprises:
(a) coupling a compound of formula II or IIa
wherein R has meaning as defined; Ra is lower alkyl; and R6 and R7 represent lower alkyl; or R6 and R7 together with the nitrogen atom represent piperidino, pyrrolidino or morpholino;
with a compound of formula III
wherein R1, R2, R3, R4 and R5 have meaning as defined in said claim 1, in the presence of copper and cuprous iodide, to obtain a compound of formula IV or IVa
and hydrolyzing the resulting compound of formula IV or IVa to a compound of formula I; or
(b) for compounds in which R represents ethyl, condensing a compound of formula V
wherein R1-R7 have meaning as defined above, with a reactive functional derivative of acetic acid, such as acetyl chloride, in a Friedel-Crafts acylation reaction to obtain a compound of the formula VI
wherein R1-R7 have meaning as defined above, and which is in turn hydrogenolyzed and then hydrolyzed to obtain a compound of formula I wherein R represents ethyl; or
(c) hydrolyzing a lactam of formula VII
wherein R and R1-R5 have meaning as defined, with a strong base; and
in above processes, if desired, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound into another compound of the invention; and/or if desired converting a free carboxylic acid of the invention into a pharmaceutically acceptable ester derivative thereof; and/or if desired, converting a resulting free acid into a salt or a resulting salt into the free acid or into another salt.

### Claim 11

A compound of formula (I)
wherein
R is methyl or ethyl;
R1 is chloro or fluoro;
R2 is hydrogen or fluoro;
R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;
R4 is hydrogen or fluoro; and
R5 is methyl;
which compound is a COX-2 selective cyclooxygenase inhibitor inhibiting COX-2 without significantly inhibiting COX-1;
or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable prodrug ester thereof.

### Claim 12 (depends on 1)

A compound according to claim 1 wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen; R3 is hydrogen, fluoro, chloro, methyl or hydroxy; R4 is hydrogen; and R5 is methyl; which compound is a COX-2 selective cyclooxygenase inhibitor inhibiting COX-2 without significantly inhibiting COX-1; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable prodrug ester thereof.

### Claim 13 (depends on 1)

A compound according to claim 1 wherein the pharmaceutically acceptable prodrug ester is a nitrooxy-lower alkyl ester.

### Claim 14 (depends on 3)

A method of treating cyclooxygenase-2 dependent disorders in mammals while substantially eliminating undesirable side effects associated with cyclooxygenase-1 inhibiting activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of claim 3 which is substantially free of cyclooxygenase-1 inhibiting activity.

### Claim 15 (depends on 3)

A method of selectively inhibiting cyclooxygenase-2 activity in a mammal without substantially inhibiting cycloxygenase-1 activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of claim 3 which is substantially free of cyclooxygenase-1 inhibiting activity.

### Claim 16 (depends on 3)

A method of treating rheumatoid arthritis, osteoarthritis, pain, inflammation in mammals which comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of claim 3 which is substantially free of gastrointestinal ulceration.

### Claim 17 (depends on 3)

A method of treating ocular inflammatory disorders, glaucoma or dry eye disease in mammals which comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of claim 3.
